Clinical trials: Solid Tumor Cancers
Cancer, Malignancy
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient.
- Conditions
- Cancer, Malignancy, Refractory Cancer, Relapsed Cancer
- Trial name
- ANGELICA (NCT05302037)
- Testing
- Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Advanced Solid Tumors
CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.
- Trial name
- NCT03113188
- Testing
- CBP501
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- CanBas Co. Ltd.
Advanced Solid Tumor, Hematological Malignancy
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
- Trial name
- NCT06225856
- Testing
- YY201
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Advanced Solid Tumors
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
The purpose of this study is to compare the pharmacokinetics of trifluorothymidine (FTD) as a component of TAS-102 with FTD alone.
- Trial name
- NCT01867866
- Testing
- TAS-102, Trifluridine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Solid Tumor
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT01875705
- Testing
- GDC-0994
- Where
- 4 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
This study evaluates the safety, tolerance, pharmacokinetics (PK), and antitumor activity of ADCT-601 in patients with advanced solid tumors.
- Trial name
- NCT03700294
- Testing
- ADCT-601
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ADC Therapeutics S.A.
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Neoplasms
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
The primary objective of this trial is to determine the Maximum Tolerated Dose (MTD) of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly.
- Trial name
- NCT00998296
- Testing
- BIBW 2992, BIBF 1120
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Melanoma Neoplasms
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
This is a Phase I, open-label, dose-escalating, study of the safety and tolerability of KU-0059436 in combination with DTIC in the treatment of patients with advanced melanoma who have not previously received systemic cytotoxic…
- Trial name
- NCT00516802
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate Bupropion and metabolite Hydroxy bupropion in Advanced solid tumor…
- Trial name
- NCT04457180
- Testing
- Apatinib Mesylate, Repaglinide, Bupropion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor
A Study of HS-20089 in Patients With Advanced Solid Tumors
HS-20089 is a novel DAR-6 antibody-drug conjugate （ADC） targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo.
- Trial name
- NCT05263479
- Testing
- HS-20089 (Phase Ia：Dose escalation ), HS-20089 (Phase Ib: Dose expansion)
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd
Tumors
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate
- Trial name
- NCT00437437
- Testing
- Brivanib
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT07554196
- Testing
- HH-101 (0.3 mg/kg), HH-101 (1 mg/kg ), HH-101 (3 mg/kg )
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Huahui Health
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Malignant Solid Tumors
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.
- Trial name
- NCT06737731
- Testing
- SHR-1681
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
A Study YL201 in Patients With Selected Advanced Solid Tumors
This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors.
- Trial name
- NCT06057922
- Testing
- YL201 for Injection
- Where
- 52 sites in China
- Volunteers
- 990 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced or Metastatic Solid Tumors
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05785754
- Testing
- DCSZ11, Pembrolizumab, Doxorubicin
- Where
- 35 sites in United States, Australia and 2 more
- Volunteers
- 320 people
- Sponsor
- DynamiCure Biotechnology
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.